General
Preferred name
HALOPEMIDE
Synonyms
R 34,301 ()
HALOPEMIDA ()
R-34301 ()
NSC-354856 ()
P&D ID
PD021473
CAS
59831-65-1
Tags
available
drug candidate
Drug indication
Discovery agent
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].
PRICE 111
DESCRIPTION Halopemide is a potent inhibitor of phospholipase D (PLD), and also a dopamine blocker. It is structurally related to butyrophenones and acts as a psychotropic agent, without parkinsonian side effects. (BOC Sciences Bioactive Compounds)
DESCRIPTION Halopemide is a potent inhibitor of PLD (IC50 = 220 and 310 nM for human PLD1 and PLD2). Halopemid is an antagonist of dopamine receptors. Halopemid can be used in psychotropic research. (TargetMol Bioactive Compound Library)
Compound Sets
14
BOC Sciences Bioactive Compounds
halopemide-cas-59831-65-1-item-29636
Cayman Chemical Bioactives
13205
ChEMBL Drugs
CHEMBL245621
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugMAP
DMF6V8W
DrugMatrix
EUbOPEN Chemogenomics Library
EUB0000775
JUMP-MOA Compound Set
65490
JUMP-Target 1 Compound Set
65490
MedChem Express Bioactive Compound Library
HY-119093
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
T15461
External IDs
23
Properties
(calculated by RDKit )
Molecular Weight
416.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
3.19
TPSA
70.13
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Dopamine Receptor
Phospholipase
PLD1
PLD2
PLD1, PLD2
Member status
member
MOA
Dopamine Receptor Antagonists
Phospholipase D2 (PLD2) Inhibitors
Phospholipase inhibitor
Pathway
GPCR/G protein
Metabolic Enzyme/Protease
Neuronal Signaling
Metabolism
Neuroscience
Recommended Cell Concentration
100 nM
Source data